Homepage > Projects > Monaco’s Official Development Assistance projects > Multi-country > multi-country > MMV390048: stimulating research in Africa into combating malaria

MMV390048: stimulating research in Africa into combating malaria

Project leader

Medicines for Malaria Venture

Location Afrique
Duration 2016 - 2019
Intervention Area Health
Funding 350 000,00 €


In 15 years, malaria-related deaths have decreased by 47% worldwide (saving 4.3 million lives), but 3.4 billion people are still at risk of malaria. The pandemic causes around 600,000 deaths per year, of which 90% are in Sub-Saharan Africa and more than 300,000 are children (one child every minute). The economic cost of malaria in Africa is estimated at 12 billion dollars.

Combating malaria, is a key programme of the Government of Monaco, for which health is the main priority area of activity. Through this project, the Government aims to contribute to SDG No. 3, "Ensure healthy lives and promote well-being for all at all ages".

Medicines for Malaria Venture (MMV) is a Swiss foundation, founded approximately 15 years ago, which resulted from an internationally recognised public/private partnership working closely with the WHO and Roll Back Malaria. 
Monaco will be involved alongside financial backers such as the B & M Gates Foundation and the UK Department for International Development.

The aim of this Programme is to develop an effective drug that will make it possible to circumvent the phenomenon of resistance to the existing molecules, is well tolerated by children and pregnant women, has a long shelf life in a tropical climate, is administered orally in a single dose and is affordable (less than 1USD) for people living in conditions of extreme poverty. It is thus complementary to the current areas of activity of Monaco's Official Development Assistance in this field (building the capacity of countries with regard to the prevention and treatment of people with this disease).

This will be the first antimalarial drug discovered by an African team to reach the clinical trials stage and co-financed by an African agency (the South AfricanTechnology Innovation Agency - TIA).

Project owner 

Medicines for Malaria Venture.

Overall objective

To bring a drug candidate to phase III in order to develop a new antimalarial drug and a formula that is also suitable for paediatric use and for pregnant women.


Direct beneficiaries:

  • African researchers, who will benefit from capacity building
  • Patients taking part in the clinical trial
  • Children and adults in the endemic countries


Indirect beneficiaries:

  • The patients' families
  • Local communities and economies

Anticipated outcomes 

  1. The efficacy of the drug is confirmed
  2. The two drugs studied show no interaction at the metabolic level
  3. The drug combination in a single dose (single dose cure) is effective